Lineage Cell Therapeutics Net Income 2006-2021 | LCTX

Lineage Cell Therapeutics net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Lineage Cell Therapeutics Annual Net Income
(Millions of US $)
2020 $-21
2019 $-12
2018 $-46
2017 $-20
2016 $34
2015 $-47
2014 $-36
2013 $-44
2012 $-21
2011 $-17
2010 $-11
2009 $-5
2008 $-4
2007 $-1
2006 $-2
2005 $-2
Lineage Cell Therapeutics Quarterly Net Income
(Millions of US $)
2021-06-30 $-5
2021-03-31 $-1
2020-12-31 $2
2020-09-30 $-8
2020-06-30 $-7
2020-03-31 $-8
2019-12-31 $-4
2019-09-30 $-17
2019-06-30 $-30
2019-03-31 $39
2018-12-31 $-45
2018-09-30 $67
2018-06-30 $-4
2018-03-31 $-64
2017-12-31 $-72
2017-09-30 $14
2017-06-30 $-12
2017-03-31 $49
2016-12-31 $-5
2016-09-30 $31
2016-06-30 $25
2016-03-31 $-17
2015-12-31 $-14
2015-09-30 $-14
2015-06-30 $-10
2015-03-31 $-10
2014-12-31 $-11
2014-09-30 $-8
2014-06-30 $-10
2014-03-31 $-8
2013-12-31 $-20
2013-09-30 $-9
2013-06-30 $-8
2013-03-31 $-8
2012-12-31 $-6
2012-09-30 $-5
2012-06-30 $-5
2012-03-31 $-5
2011-12-31 $-5
2011-09-30 $-4
2011-06-30 $-4
2011-03-31 $-3
2010-12-31 $-3
2010-09-30 $-5
2010-06-30 $-2
2010-03-31 $-1
2009-12-31 $1
2009-09-30 $-4
2009-06-30 $-1
2009-03-31 $-2
2008-12-31 $-2
2008-09-30 $-1
2008-06-30 $-1
2008-03-31 $-0
2007-12-31 $-0
2007-09-30 $-0
2007-06-30 $-0
2007-03-31 $-1
2006-12-31 $-0
2006-09-30 $-0
2006-06-30 $-1
2006-03-31 $-0
2005-12-31 $-0
2005-09-30 $-0
2005-06-30 $-0
2005-03-31 $-1
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.383B $0.002B
Lineage Cell Therapeutics Inc. is a clinical-stage biotechnology company. It focuses on developing and commercializing therapies for the treatment of degenerative diseases primarily in the United States and internationally. The company's lead product candidates include OpRegen, OPC1 and VAC2 which are in clinical stage. Lineage Cell Therapeutics Inc., formerly known as BioTime Inc., is based in Carlsbad, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.527B 7.92
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.184B 20.63
Biohaven Pharmaceutical Holding (BHVN) United States $8.967B 0.00
Emergent Biosolutions (EBS) United States $2.590B 6.25
Arcus Biosciences (RCUS) United States $2.362B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.929B 0.00
Myovant Sciences (MYOV) United Kingdom $1.832B 0.00
Zymeworks (ZYME) Canada $1.055B 0.00
Ambrx Biopharma (AMAM) United States $0.463B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.67